FUJIFILM Listed by sarcoma Ransomware Group
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy.
Related breaches
Mercado Libre Listed by thegentlemen Ransomware Group
***.com.ar zoominfo.com/c/mercadolibre-srl/425378760 Argentine platform of MercadoLibre, the undispu…
tecnocurva.com.br Listed by incransom Ransomware Group
Company operating in the automotive sector. Heavy and agricultural segment. Forming of tubes and wel…
hive360.com Listed by dragonforce Ransomware Group
HIVE360 is a UK-based employment administration and employee benefits specialist. They help business…
A breach leaks your credentials. Then hackers chain those credentials to your address, family, phone, and employer using public broker sites. We’re the only tool built around that chain.
⚠ Were you in this breach?
Free email scanner. We check your address against 15.4B+ leaked records in 15 seconds — then show you the $19 cleanup that removes you from the broker sites aggregating leaked data.
Check my email — free →